WHO WE ARE

Serina Therapeutics, Inc. is a privately held pharmaceutical company located at the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama. We have developed a proprietary polymer technology called POZ™ that is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety and quality of life for patients.

COMPANY OVERVIEW

Serina Therapeutics, Inc. was founded in 2006 by Drs. Milton Harris and Michael Bentley who developed and patented much of the polymer technology known as PEG, or PEGylation, during their work at Shearwater Polymers and Nektar Therapeutics. PEG became widely accepted as the polymer standard for drug development. Today, greater than $120 B of cumulative product sales can be attributed to this technology.

MANAGEMENT

Randall Moreadith

Randall Moreadith, M.D., Ph.D.

President and Chief Executive Officer

Michael Bentley

Michael Bentley, Ph.D.

Founder, Chief Scientific Officer

Tacey Viegas

Tacey Viegas, Ph.D.

Chief Operating Officer

J Milton Harris

J. Milton Harris, Ph.D.

Founder, Chairman of the Board

Brendan P. Rae, Ph.D., J.D.

Chief Business Officer

BOARD OF DIRECTORS

J. Milton Harris, Ph.D.

Founder, Chairman of the Board

Michael Bentley, Ph.D.

Founder, Chief Scientific Officer

Barbara Fisk

James R. Hudson, Jr.

Lonnie S. McMillian

Director Emeritus

Michael Loya

Randall Moreadith, M.D., Ph.D.

President and Chief Executive Officer

CLINICAL ADVISORY BOARD

Marshall Schreeder, M.D.

Chair, Serina Clinical Advisory Board

David G. Standaert, M.D., Ph.D.

C. Warren Olanow, M.D.